The rate of use of high-cost operative procedures is not lower among Medicare beneficiaries enrolled in for-profit health plans than among those enrolled in not-for-profit health plans, according to a study in the New England Journal of Medicine (2004; 350:143-150).
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.